Improving diagnosis and treatment for type 2 inflammatory skin diseases
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project: a National Multicenter Prospective Cohort Study
This study is trying to improve how we diagnose and treat type 2 inflammatory skin diseases like atopic dermatitis by creating a specialized center and looking at different treatment methods to see what works best.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100000 (estimated) |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05316805 on ClinicalTrials.gov |
What this trial studies
This project aims to enhance the diagnosis and treatment of type 2 inflammatory skin diseases, such as atopic dermatitis and prurigo nodularis, by establishing a standardized center for these conditions. The initiative will systematically assess the current treatment practices and evaluate the efficacy and safety of various treatment methods. By gathering and analyzing data from patients diagnosed with these skin diseases, the project seeks to improve overall treatment outcomes and patient care.
Who should consider this trial
Good fit: Ideal candidates for this project are patients diagnosed with type 2 inflammatory skin diseases who are receiving treatment at approved medical units.
Not a fit: Patients who are unable to provide informed consent or complete the necessary questionnaires may not benefit from this project.
Why it matters
Potential benefit: If successful, this project could lead to better management and treatment options for patients suffering from type 2 inflammatory skin diseases.
How similar studies have performed: Other studies focusing on standardized treatment approaches for inflammatory skin diseases have shown promise, indicating potential for success in this project.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details); 2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema, urticaria, pemphigoid, prurigo nodularis). Exclusion Criteria: 1. patients who fail to provide informed consent form; 2. patients who cannot complete the questionnaire independently or under the guidance of investigators
Where this trial is running
Beijing
- Peking University First Hospital — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Yang Wang, Doctor
- Email: yangwang_dr@bjmu.edu.cn
- Phone: 008613811232795
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.